Skip to main content

Month: May 2021

Diabetes Drugs Market Size 2021 | Is Projected to Reach USD 78261.1 Million by 2026, Exhibiting a CAGR of 6.1%

Diabetes Drugs Market Key Players Studied in this Report Are Novo Nordisk A/S, Sanofi, Merck & Co., Inc, Eli Lilly and Company, AstraZeneca, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Novartis AG, Johnson & Johnson Services, Inc, Bayer AG. Pune, India, May 24, 2021 (GLOBE NEWSWIRE) — According to the report, Diabetes Drugs market size is projected to reach USD 78261.1 Million value by 2026, exhibiting a CAGR of 6.1%. The report further mentions that the market stood at USD 48753.1 million in 2018. The drugs are administered through oral, subcutaneous, and intravenous routes. It is utilized to treat diabetes Type 1 and Type 2. According to the Centers for Disease Control and Prevention in 2017, the US alone accounted for 30.3 million diabetic patients. The increasing prevalence of diabetes...

Continue reading

Volta Finance Limited : Misleading Website

24 May 2021 Volta Finance Limited (VTA / VTAS) Misleading Website   The Board of Volta Finance Limited announces the discovery of a website purporting to represent Volta Investment Group (“VIG”), an entity entirely unrelated to Volta Finance Limited (“the Company”). The website for VIG incorrectly notes that a number of the Directors of the Company are involved with VIG as members of their board. In addition to the incorrect information regarding their board, it was also noted that the Companies House (UK) Certificate of Incorporation displayed on the website of VIG does not match the details and documentation publically available from Companies House.   Further to the discovery of VIG’s website, the Company contacted the webhosting provider and the domain registrar of the website to alert them to the incorrect and misleading information...

Continue reading

Blood Transfusion Diagnostics Market Size 2021 | Is Projected to Reach USD 7.08 Billion by 2028, Exhibiting a CAGR of 7.1%

Top Players Covered in the Blood Transfusion Diagnostics Market Research Report Are Grifols, S.A. (Barcelona, Spain), Immucor, Inc. (Georgia, United States), Bio-Rad Laboratories, Inc. (California, United States), Ortho Clinical Diagnostics (New Jersey, United States), F. Hoffmann-La Roche Ltd (Basel, Switzerland), QUOTIENT (Eysins, Switzerland), Merck KGaA (Darmstadt, Germany), Abbott (Illinois, United States) and other key market players. Pune, India, May 24, 2021 (GLOBE NEWSWIRE) — Blood Transfusion Diagnostics Market Size| 2021 Covid-19 Impact On Healthcare Industry Global Analysis By Size, Trends, Growth, Share, Business, Key Players, Merger, Statistics, Competitive Landscape, And Regional Forecast To 2026 is latest study published by Fortune Business Insights. The global blood transfusion diagnostics market size is projected...

Continue reading

Itamar Medical Appoints Brad Fluegel to its Board of Directors

CAESAREA, Israel, May 24, 2021 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its Board of Directors. Mr. Fluegel’s vast experience includes wide ranging leadership roles and 25+ years in the healthcare sector, primarily in strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for driving all commercial healthcare activities, including sales and contracting, biopharma relationships, retail clinics, clinical affairs, new service development and market planning. Prior, he served as Walgreens’...

Continue reading

Genetron Health Reports First Quarter 2021 Unaudited Financial Results

BEIJING, May 24, 2021 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the first quarter ended March 31, 2021. First Quarter 2021 HighlightsRecorded total revenue of RMB 92.1 million (US$14.1 million) for the first quarter 2021, representing a 19.8% increase over the same period of 2020. Excluding revenue from Genetron’s SARS-CoV-2 RNA test for COVID-19 of RMB 16.6 million in the first quarter of 2020, total revenue grew 52.9% year over year. LDT segment revenue grew 51.0% to RMB 71.8 million (US$11.0 million), driven by HCCscreenTM, the Company’s...

Continue reading

A Sustainable Year: CNH Industrial presents its 2020 highlights with a dedicated interactive sit

CNH INDUSTRIAL N.V.CNH Industrial A Sustainable Year 2020CNH Industrial has published the companion guide to its 2020 Sustainability Report. For the first time, this edition of A Sustainable Year is proposed as an interactive online magazine. Visit publications.cnhindustrial.com/a-sustainable-year to read up on how the Company made the most of a challenging year from safeguarding employees to improving its environmental footprint, enhancing its products, technologies and digital capabilities for the good of all and reaching out to support communities in need. London, May 24, 2021 In a year that will remain impressed on history, where many could have stood still without question or fault, CNH Industrial (NYSE: CNHI / MI: CNHI), ten-time Industry Leader in the Dow Jones Sustainability World and Europe Indices, pursued...

Continue reading

UTStarcom Names Hua Li as New Chief Executive Officer and Announces Changes to Its Board of Directors

HANGZHOU, China, May 24, 2021 (GLOBE NEWSWIRE) — UTStarcom (“UT” or the “Company”) (NASDAQ: UTSI), a global telecommunications infrastructure provider, today named Mr. Hua Li as the Company’s new Chief Executive Officer, effective June 16, 2021 and announced changes to the Board of Directors, effective May 19, 2021. New Chief Executive Officer  Mr. Li, a TDI nominee, brings nearly eight years of business and management experience to the Company. He previously served as the General Manager of Hangzhou Yi Yi Tai Di Information Technology Co., Ltd. Prior to that, Mr. Li served as the Deputy General Manager of Jiangsu Tongding Broadband Co., Ltd. Earlier, he served as Beijing office director of Jiangsu Tongding Optoelectronic Co., Ltd. He was awarded the senior engineer qualification by Zhejiang Software Industry Association in 2021....

Continue reading

China Index Holdings Receives Notification from Nasdaq for Failure to Timely File Form 20-F

BEIJING, May 24, 2021 (GLOBE NEWSWIRE) — China Index Holdings Limited (NASDAQ: CIH), (“CIH” or the “Company”), a leading real estate information and analytics service platform provider in China, today reports that as of May 18, 2021, it is delinquent in filing its annual report on Form 20-F for the fiscal year ended December 31, 2020 (the “2020 Form 20-F”) with the U.S. Securities and Exchange Commission (the “SEC”). The Company previously filed a Form 12b-25 with the SEC on May 3, 2021 for late filing of the 2020 Form 20-F, pursuant to which the 2020 Form 20-F was due to be filed by May 17, 2021. The Company expects to file the 2020 Form 20-F (i) upon the outcome of the negotiation between Fang Holdings Limited (“Fang”) and its convertible note holders for the repayment schedule of the outstanding amount under the convertible...

Continue reading

OBITX, Inc. Announces Company Name Change to Everything Blockchain, Inc.

Jacksonville, FL, May 24, 2021 (GLOBE NEWSWIRE) —Focusing on its blockchain and decentralized processing business acumen, OBITX, Inc., rebrands their company name and image. OBITX, INC. (OTC Markets: OBTX)  OBITX, Inc., an industry leader in blockchain development, engineering, and consulting has announced today that the company will begin operating under a new name and will be known as Everything Blockchain, Inc.  The Company filed the appropriate documents with the state of Delaware on May 19, 2021.  The Company will file with FINRA to begin the process of updating its name and ticker symbol.  The Company will announce the effective date upon final notification and approval from FINRA. This rebranding strategy reflects both the evolution of the company as well as its vision for the future. Along with this change, a newly...

Continue reading

Registration of the reduced quantity of shares in Nexstim Plc (the last phase)

Company announcement, Helsinki, 24 May 2021 at 11:00 AM (EEST) Registration of the reduced quantity of shares in Nexstim Plc (the last phase) The Annual General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) resolved on 11 May 2021 to reduce the quantity of Nexstim’s shares without reducing share capital by way of issuing new shares and by redemption of Company’s own shares, in such a way that each current 100 shares of the Company shall correspond to one share of the Company after the arrangements related to the reduction of the quantity of Company’s shares are completed. Pursuant to the resolution of the Board of Directors of the Company on 21 May 2021 regarding issue / transfer of shares of the Company without consideration, and the annulment of the remaining treasury shares (as set forth in...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.